Form 10-Q · Quarterly report
Abbott Laboratories 10-Q, filed Nov 4, 2026
- Filed
- CIK
- 0000001800
- Accession no.
- 0001628280-26-070154
Summary
Abbott Laboratories reported third-quarter 2026 net sales of $13.0 billion, up 14.5% from a year earlier (14.8% excluding foreign exchange), driven by its acquisition of Exact Sciences and growth in Medical Devices and Established Pharmaceutical Products. Abbott said it completed the Exact Sciences purchase on March 23, 2026 for about $20.6 billion, with those results reported as Cancer Diagnostics within its Diagnostic Products segment.
Key points
- Third-quarter 2026 Diagnostic Products sales rose 46.7% to $3.3 billion, primarily from the Exact Sciences acquisition, while Medical Devices sales rose 6.9% to $5.8 billion.
- Gross profit margin was 50.3% in the third quarter of 2026 versus 51.7% a year earlier, which Abbott attributed mainly to higher intangible amortization from Exact Sciences, higher costs, and foreign exchange.
- Abbott said it received FDA approval in August 2026 for Libre Duo, its dual glucose-ketone biowearable sensor, and FDA approval in September 2026 for the TactiFlex Duo Ablation Catheter, which delivers pulsed field and radiofrequency energy.
- Abbott launched SimpleScreen CRC, an FDA-approved blood-based colorectal cancer screening test for adults 45 and older at average risk, in September 2026, and received CE Mark for its Amulet 360 Left Atrial Appendage Occluder in August 2026.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations Financial Review — Results of Operations Abbott’s revenues are derived primarily from the sale of a broad portfolio of healthcare products under short-term receivable arrangements. Patent protection and licenses, technological and performance features, and inclusion of Abbott’s products under a contract most significantly impact which products are sold; price controls, competition, and rebates most significantly impact the net selling prices of products; and foreign currency translation impacts the measurement of net sales and costs. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.